Siju C George, Santiago Aguirre, Nichole M Maughan, Ranjini Tolakanahalli, E James Jebaseelan Samuel, Sven L Gallo, Jacqueline E Zoberi, Yongsook C Lee
{"title":"提高安全性:基于 177 Lu $^{177}{rm Lu}$ 的放射性药物疗法的多机构 FMEA 和 FTA。","authors":"Siju C George, Santiago Aguirre, Nichole M Maughan, Ranjini Tolakanahalli, E James Jebaseelan Samuel, Sven L Gallo, Jacqueline E Zoberi, Yongsook C Lee","doi":"10.1002/acm2.14550","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates potential failure modes and conducts failure mode and effects analysis (FMEA) and fault tree analysis (FTA) on the administration of <math> <semantics> <mrow><msup><mrow></mrow> <mn>177</mn></msup> <mi>Lu</mi></mrow> <annotation>$^{177}{\\rm Lu}$</annotation></semantics> </math> DOTATATE (LUTATHERA) and <math> <semantics> <mrow><msup><mrow></mrow> <mn>177</mn></msup> <mi>Lu</mi></mrow> <annotation>$^{177}{\\rm Lu}$</annotation></semantics> </math> PSMA-617 (PLUVICTO). The quality management (QM) process in radiopharmaceutical therapies (RPTs) requires collaboration between nuclear medicine (NM) and radiation oncology (RO) departments. As part of a multi-institutional study, we surveyed various departments to identify and analyze failure modes, leading to a proposed comprehensive QM program. RPT teams in RO or NM clinics can benefit from this study by continually improving their practice.</p><p><strong>Methods: </strong>We reviewed the literature to investigate the administration of Pluvicto and Lutathera, focusing on prospective procedural failures and potential failure modes (PFMs) and their outcomes. We distributed an FMEA survey to multiple experienced centers in <math> <semantics> <mrow><msup><mrow></mrow> <mn>177</mn></msup> <mi>Lu</mi></mrow> <annotation>$^{177}{\\rm Lu}$</annotation></semantics> </math> -based RPTs and calculated risk priority number (RPN) for various PFM. We conducted an FTA using this information to pinpoint the root causes of potential failures.</p><p><strong>Results: </strong>The findings from the literature review and survey responses on the prospective study have identified several critical areas at risk of failure. These areas include non-optimized treatment delivery, inadequate patient monitoring, and lack of safety training, leading to radiation contamination from the dose excreted by the patients after treatment administration. A segmented FTA was created based on the FMEA results, focusing on radiation contamination with a high RPN value.</p><p><strong>Conclusion: </strong>By identifying the root causes of failures and proposing targeted improvements to the existing QM measures, this analysis enhances safety in treatment delivery of <math> <semantics> <mrow><msup><mrow></mrow> <mn>177</mn></msup> <mi>Lu</mi></mrow> <annotation>$^{177}{\\rm Lu}$</annotation></semantics> </math> -based RPTs. Given the limited number of prospective risk analysis studies in RPTs, our research addresses the necessity for more such studies and recommends methods to apply this study to other RPTs.</p>","PeriodicalId":14989,"journal":{"name":"Journal of Applied Clinical Medical Physics","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<ArticleTitle xmlns:ns0=\\\"http://www.w3.org/1998/Math/MathML\\\">Enhancing safety: Multi-institutional FMEA and FTA on <ns0:math> <ns0:semantics> <ns0:mrow><ns0:msup><ns0:mrow /> <ns0:mn>177</ns0:mn></ns0:msup> <ns0:mi>Lu</ns0:mi></ns0:mrow> <ns0:annotation>$^{177}{\\\\rm Lu}$</ns0:annotation></ns0:semantics> </ns0:math> -based radio-pharmaceutical therapy.\",\"authors\":\"Siju C George, Santiago Aguirre, Nichole M Maughan, Ranjini Tolakanahalli, E James Jebaseelan Samuel, Sven L Gallo, Jacqueline E Zoberi, Yongsook C Lee\",\"doi\":\"10.1002/acm2.14550\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>This study investigates potential failure modes and conducts failure mode and effects analysis (FMEA) and fault tree analysis (FTA) on the administration of <math> <semantics> <mrow><msup><mrow></mrow> <mn>177</mn></msup> <mi>Lu</mi></mrow> <annotation>$^{177}{\\\\rm Lu}$</annotation></semantics> </math> DOTATATE (LUTATHERA) and <math> <semantics> <mrow><msup><mrow></mrow> <mn>177</mn></msup> <mi>Lu</mi></mrow> <annotation>$^{177}{\\\\rm Lu}$</annotation></semantics> </math> PSMA-617 (PLUVICTO). The quality management (QM) process in radiopharmaceutical therapies (RPTs) requires collaboration between nuclear medicine (NM) and radiation oncology (RO) departments. As part of a multi-institutional study, we surveyed various departments to identify and analyze failure modes, leading to a proposed comprehensive QM program. RPT teams in RO or NM clinics can benefit from this study by continually improving their practice.</p><p><strong>Methods: </strong>We reviewed the literature to investigate the administration of Pluvicto and Lutathera, focusing on prospective procedural failures and potential failure modes (PFMs) and their outcomes. We distributed an FMEA survey to multiple experienced centers in <math> <semantics> <mrow><msup><mrow></mrow> <mn>177</mn></msup> <mi>Lu</mi></mrow> <annotation>$^{177}{\\\\rm Lu}$</annotation></semantics> </math> -based RPTs and calculated risk priority number (RPN) for various PFM. We conducted an FTA using this information to pinpoint the root causes of potential failures.</p><p><strong>Results: </strong>The findings from the literature review and survey responses on the prospective study have identified several critical areas at risk of failure. These areas include non-optimized treatment delivery, inadequate patient monitoring, and lack of safety training, leading to radiation contamination from the dose excreted by the patients after treatment administration. A segmented FTA was created based on the FMEA results, focusing on radiation contamination with a high RPN value.</p><p><strong>Conclusion: </strong>By identifying the root causes of failures and proposing targeted improvements to the existing QM measures, this analysis enhances safety in treatment delivery of <math> <semantics> <mrow><msup><mrow></mrow> <mn>177</mn></msup> <mi>Lu</mi></mrow> <annotation>$^{177}{\\\\rm Lu}$</annotation></semantics> </math> -based RPTs. Given the limited number of prospective risk analysis studies in RPTs, our research addresses the necessity for more such studies and recommends methods to apply this study to other RPTs.</p>\",\"PeriodicalId\":14989,\"journal\":{\"name\":\"Journal of Applied Clinical Medical Physics\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-11-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Applied Clinical Medical Physics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/acm2.14550\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Clinical Medical Physics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/acm2.14550","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
目的:本研究调查了177 Lu $^{177}{\rm Lu}$ DOTATATE(LUTATHERA)和177 Lu $^{177}{\rm Lu}$ PSMA-617 (PLUVICTO)的潜在失效模式,并进行了失效模式与效应分析(FMEA)和故障树分析(FTA)。放射性药物治疗(RPT)的质量管理(QM)过程需要核医学(NM)和放射肿瘤学(RO)部门之间的合作。作为一项多机构研究的一部分,我们对各部门进行了调查,以确定和分析失败模式,从而提出了一项全面的质量管理计划。放射肿瘤科或 NM 诊所的 RPT 团队可以从这项研究中受益,不断改进他们的实践:我们查阅了相关文献,调查了 Pluvicto 和 Lutathera 的使用情况,重点关注了前瞻性程序故障和潜在故障模式 (PFM) 及其结果。我们向多个经验丰富的中心发放了基于177 Lu $^{177}{\rm Lu}$ RPT的FMEA调查表,并计算了各种PFM的风险优先级(RPN)。我们利用这些信息进行了一次 FTA,以找出潜在故障的根本原因:结果:文献综述和前瞻性研究调查的结果确定了几个存在故障风险的关键领域。这些领域包括未优化治疗实施、患者监测不足以及缺乏安全培训,从而导致治疗实施后患者排出的剂量造成辐射污染。根据 FMEA 结果创建了一个分段 FTA,重点关注 RPN 值较高的辐射污染:通过找出故障的根本原因并对现有的质量管理措施提出有针对性的改进建议,该分析提高了基于 177 Lu $^{177}{\rm Lu}$ 的 RPT 治疗的安全性。鉴于RPT前瞻性风险分析研究的数量有限,我们的研究提出了进行更多此类研究的必要性,并推荐了将本研究应用于其他RPT的方法。
Enhancing safety: Multi-institutional FMEA and FTA on 177Lu$^{177}{\rm Lu}$ -based radio-pharmaceutical therapy.
Purpose: This study investigates potential failure modes and conducts failure mode and effects analysis (FMEA) and fault tree analysis (FTA) on the administration of DOTATATE (LUTATHERA) and PSMA-617 (PLUVICTO). The quality management (QM) process in radiopharmaceutical therapies (RPTs) requires collaboration between nuclear medicine (NM) and radiation oncology (RO) departments. As part of a multi-institutional study, we surveyed various departments to identify and analyze failure modes, leading to a proposed comprehensive QM program. RPT teams in RO or NM clinics can benefit from this study by continually improving their practice.
Methods: We reviewed the literature to investigate the administration of Pluvicto and Lutathera, focusing on prospective procedural failures and potential failure modes (PFMs) and their outcomes. We distributed an FMEA survey to multiple experienced centers in -based RPTs and calculated risk priority number (RPN) for various PFM. We conducted an FTA using this information to pinpoint the root causes of potential failures.
Results: The findings from the literature review and survey responses on the prospective study have identified several critical areas at risk of failure. These areas include non-optimized treatment delivery, inadequate patient monitoring, and lack of safety training, leading to radiation contamination from the dose excreted by the patients after treatment administration. A segmented FTA was created based on the FMEA results, focusing on radiation contamination with a high RPN value.
Conclusion: By identifying the root causes of failures and proposing targeted improvements to the existing QM measures, this analysis enhances safety in treatment delivery of -based RPTs. Given the limited number of prospective risk analysis studies in RPTs, our research addresses the necessity for more such studies and recommends methods to apply this study to other RPTs.
期刊介绍:
Journal of Applied Clinical Medical Physics is an international Open Access publication dedicated to clinical medical physics. JACMP welcomes original contributions dealing with all aspects of medical physics from scientists working in the clinical medical physics around the world. JACMP accepts only online submission.
JACMP will publish:
-Original Contributions: Peer-reviewed, investigations that represent new and significant contributions to the field. Recommended word count: up to 7500.
-Review Articles: Reviews of major areas or sub-areas in the field of clinical medical physics. These articles may be of any length and are peer reviewed.
-Technical Notes: These should be no longer than 3000 words, including key references.
-Letters to the Editor: Comments on papers published in JACMP or on any other matters of interest to clinical medical physics. These should not be more than 1250 (including the literature) and their publication is only based on the decision of the editor, who occasionally asks experts on the merit of the contents.
-Book Reviews: The editorial office solicits Book Reviews.
-Announcements of Forthcoming Meetings: The Editor may provide notice of forthcoming meetings, course offerings, and other events relevant to clinical medical physics.
-Parallel Opposed Editorial: We welcome topics relevant to clinical practice and medical physics profession. The contents can be controversial debate or opposed aspects of an issue. One author argues for the position and the other against. Each side of the debate contains an opening statement up to 800 words, followed by a rebuttal up to 500 words. Readers interested in participating in this series should contact the moderator with a proposed title and a short description of the topic